Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China
· Delayed Price · Currency is CNY 17.21
+0.30 (1.77%)
Mar 10, 2026, 3:00 PM CST
Cisen Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 3,553 | 3,972 | 4,451 | 4,049 | 3,773 | 3,666 | Upgrade
|
| Other Revenue | 10.02 | 10.02 | 11.14 | 16.83 | 9.62 | 8.28 | Upgrade
|
| Revenue | 3,563 | 3,982 | 4,462 | 4,066 | 3,783 | 3,674 | Upgrade
|
| Revenue Growth (YoY) | -16.26% | -10.77% | 9.74% | 7.50% | 2.95% | -10.66% | Upgrade
|
| Cost of Revenue | 1,689 | 1,813 | 1,913 | 1,827 | 1,728 | 1,610 | Upgrade
|
| Gross Profit | 1,875 | 2,168 | 2,550 | 2,239 | 2,055 | 2,064 | Upgrade
|
| Selling, General & Admin | 1,153 | 1,367 | 1,600 | 1,544 | 1,455 | 1,355 | Upgrade
|
| Research & Development | 291.41 | 342.64 | 374.88 | 335.17 | 334.35 | 309.58 | Upgrade
|
| Other Operating Expenses | 26.85 | -4.28 | 20.97 | 55.37 | 50.31 | 45.07 | Upgrade
|
| Operating Expenses | 1,477 | 1,702 | 1,999 | 1,948 | 1,841 | 1,706 | Upgrade
|
| Operating Income | 397.49 | 466.89 | 550.79 | 291.2 | 214.24 | 357.94 | Upgrade
|
| Interest Expense | -1.75 | -6.95 | -6.59 | -4.29 | -6.1 | -9.8 | Upgrade
|
| Interest & Investment Income | 169.19 | 101.87 | 85.7 | 53 | 90.18 | 83.09 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.54 | 0.54 | 0.55 | -0.32 | -0.62 | -1.6 | Upgrade
|
| Other Non Operating Income (Expenses) | -7.75 | -0.7 | -1.27 | -0.17 | 5.21 | -3.55 | Upgrade
|
| EBT Excluding Unusual Items | 557.72 | 561.66 | 629.19 | 339.41 | 302.91 | 426.09 | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.55 | 10.53 | -10.37 | -3.12 | -6.09 | 23.03 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.25 | -0.14 | 0.59 | 0.97 | 0.27 | 0.17 | Upgrade
|
| Asset Writedown | -20.82 | -0.63 | -27.79 | 0.01 | -0.04 | -1.05 | Upgrade
|
| Other Unusual Items | 13.45 | 4.36 | 4.24 | 28.92 | 39.09 | 36.28 | Upgrade
|
| Pretax Income | 560.14 | 575.77 | 595.86 | 366.19 | 336.13 | 484.52 | Upgrade
|
| Income Tax Expense | 63.31 | 60.83 | 70.43 | 13.92 | 2.23 | 47.16 | Upgrade
|
| Earnings From Continuing Operations | 496.83 | 514.94 | 525.43 | 352.27 | 333.9 | 437.36 | Upgrade
|
| Minority Interest in Earnings | -4.03 | -6.03 | -4.09 | -2.31 | 0.24 | 1.42 | Upgrade
|
| Net Income | 492.8 | 508.91 | 521.34 | 349.96 | 334.15 | 438.78 | Upgrade
|
| Net Income to Common | 492.8 | 508.91 | 521.34 | 349.96 | 334.15 | 438.78 | Upgrade
|
| Net Income Growth | -6.84% | -2.38% | 48.97% | 4.73% | -23.85% | -14.73% | Upgrade
|
| Shares Outstanding (Basic) | 456 | 454 | 453 | 454 | 452 | 452 | Upgrade
|
| Shares Outstanding (Diluted) | 456 | 454 | 453 | 454 | 452 | 452 | Upgrade
|
| Shares Change (YoY) | 0.89% | 0.23% | -0.25% | 0.65% | -0.18% | 0.21% | Upgrade
|
| EPS (Basic) | 1.08 | 1.12 | 1.15 | 0.77 | 0.74 | 0.97 | Upgrade
|
| EPS (Diluted) | 1.08 | 1.12 | 1.15 | 0.77 | 0.74 | 0.97 | Upgrade
|
| EPS Growth | -7.67% | -2.61% | 49.35% | 4.05% | -23.71% | -14.91% | Upgrade
|
| Free Cash Flow | 701.19 | 469.04 | 433.53 | 223.15 | 182.58 | 228.74 | Upgrade
|
| Free Cash Flow Per Share | 1.54 | 1.03 | 0.96 | 0.49 | 0.40 | 0.51 | Upgrade
|
| Dividend Per Share | 0.408 | 0.440 | 0.436 | 0.335 | 0.300 | 0.256 | Upgrade
|
| Dividend Growth | -37.80% | 0.92% | 30.15% | 11.67% | 17.19% | -4.48% | Upgrade
|
| Gross Margin | 52.61% | 54.46% | 57.14% | 55.06% | 54.32% | 56.17% | Upgrade
|
| Operating Margin | 11.16% | 11.73% | 12.34% | 7.16% | 5.66% | 9.74% | Upgrade
|
| Profit Margin | 13.83% | 12.78% | 11.68% | 8.61% | 8.83% | 11.94% | Upgrade
|
| Free Cash Flow Margin | 19.68% | 11.78% | 9.71% | 5.49% | 4.83% | 6.23% | Upgrade
|
| EBITDA | 603.19 | 683.33 | 781.54 | 519.77 | 432.08 | 517.92 | Upgrade
|
| EBITDA Margin | 16.93% | 17.16% | 17.51% | 12.78% | 11.42% | 14.10% | Upgrade
|
| D&A For EBITDA | 205.7 | 216.43 | 230.75 | 228.57 | 217.84 | 159.98 | Upgrade
|
| EBIT | 397.49 | 466.89 | 550.79 | 291.2 | 214.24 | 357.94 | Upgrade
|
| EBIT Margin | 11.16% | 11.73% | 12.34% | 7.16% | 5.66% | 9.74% | Upgrade
|
| Effective Tax Rate | 11.30% | 10.56% | 11.82% | 3.80% | 0.66% | 9.73% | Upgrade
|
| Revenue as Reported | 3,563 | 3,982 | 4,462 | 4,066 | 3,783 | 3,674 | Upgrade
|
| Advertising Expenses | - | 1.47 | 0.82 | 0.2 | 0.51 | 2.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.